In NHL, aberrant activation of this pathway involves diverse mechanisms, including loss of the tumor suppressor PTEN (through mutation or inactivation), PI3Ka mutations, PI3Kd overexpression/activation, and BCR receptor activation [15–17]. Here, PTEN is linked to non-Hodgkin lymphoma.